Leadership Header Aspect Ratio 1200 384

Our Leadership

An open, experienced, and passionate team

At Vor Bio, leadership works seamlessly with the entire team to nurture and support free thinking, professional growth, and unconventional problem solving across departments and levels of seniority.

  • Robert Ang

    Robert Ang

    President and Chief Executive Officer

    Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company ...

  • Updated Headshot

    Eyal Attar, MD

    Chief Medical Officer

    Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as ...

  • Vorbiopharma Tirtha Chakraborty Sq

    Tirtha Chakraborty, PhD

    Chief Scientific Officer

    Tirtha Chakraborty, PhD brings expertise in both hematology and genetic engineering to his role as Chief Scientific Officer. He formerly served as Vor Bio’s Vice President and Head of Research. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at ...

  • Vorbiopharma Nathan Jorgensen Sq

    Nathan Jorgensen, PhD, MBA

    Chief Financial Officer

    Nathan Jorgensen PhD, MBA brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his role at Vor Bio. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, ...

  • Vorbiopharma John King Sq

    John King, MBA

    Chief Commercial Officer

    John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, ...

  • Vorbiopharma Tania Philip Sq

    Tania Philipp

    Chief People Officer

    Tania Philipp, Chief People Officer, brings more than 15 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its ...

  • Vor Headshot1 5x7 10.19 Aspect Ratio 1 1

    David Phillips, MBA

    Senior Vice President, Head of Quality

    David Phillips has more than 27 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management ...

  • Vor Headshot1 5x7 10.20 Aspect Ratio 1 1

    Samir Vattompadam, MS

    Senior Vice President, Portfolio Strategy and Program Management

    Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional ...

President and Chief Executive Officer

Robert Ang

Robert Ang, MBBS, MBA brings experience as a senior biotech executive and is formerly a physician, venture capitalist, and strategy consultant. Prior to Vor Bio, Robert was Chief Business Officer at Neon Therapeutics, serving as part of the early team that established the company prior to its Series A investment through IPO. Before Neon, he served as Senior Vice President of Business Development at Bavarian Nordic, where he was primarily responsible for conducting a $975 million transaction with Bristol-Myers Squibb for PROSTVAC, a Phase 3 immuno-oncology asset, and served as Head of Business Development and Medical Affairs for Cadence Pharmaceuticals. Robert also worked at Frazier Healthcare Ventures, a leading life sciences venture capital firm, where he was involved in several pharmaceutical and biotechnology investments including Cadence Pharmaceuticals (purchased by Mallinckrodt), Incline Therapeutics (purchased by The Medicines Company), Alnara Pharmaceuticals (purchased by Eli Lilly), and Collegium Pharmaceuticals. Robert also has strategy consulting experience at the Boston Consulting Group and has general surgical training. He holds an MBBS (Doctor of Medicine) from the University of Western Australia and an MBA with honors from Columbia Business School. Robert serves as the Board Chair of Enara Bio, a UK-based biotechnology company focused on non-classical HLA targets for immuno-oncology approaches. He is also a member of the Executive Committee of the Board of Directors of the Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies.

Robert Ang

Chief Medical Officer

Eyal Attar, MD

Eyal C. Attar, MD brings more than 20 years of demonstrated clinical excellence to his role at Vor Bio, with previous roles as a clinician, bench researcher and clinical developer of treatments for hematologic malignancies. Prior to joining Vor Bio, Eyal served as senior vice president and CMO for Aprea Therapeutics where he led development of Aprea’s lead programs, including overseeing clinical development, pharmacovigilance, and regulatory filings. Eyal worked closely on APR-246 (eprenetapopt), a cancer therapeutic pursuing indications including myelodysplastic syndromes (MDS), AML, and various solid tumors. Before Aprea, he held multiple positions in clinical development at Agios Pharmaceuticals, including Senior Medical Director and IDH Hematology Medical Lead, where he worked on various solid tumor and hematologic malignancy programs and contributed to the successful filing of multiple INDs. Eyal has played a leadership role in all aspects of clinical development from Pre-IND through to marketing authorization for several products to treat patients with newly diagnosed and relapsed/refractory AML.

Eyal was previously an attending hematologist/oncologist at Massachusetts General Hospital focusing on leukemia, MDS, and other hematologic malignancies affecting the bone marrow. He completed fellowship training at Dana-Farber Cancer Center and residency at Brigham and Women’s Hospital. Eyal received his medical degree from the University of North Carolina School of Medicine.

Vor Headshot 5x7

Chief Scientific Officer

Tirtha Chakraborty, PhD

Tirtha Chakraborty, PhD brings expertise in both hematology and genetic engineering to his role as Chief Scientific Officer. He formerly served as Vor Bio’s Vice President and Head of Research. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on hemoglobin disorders. His team’s work on autologous cell therapy using gene edited hematopoietic stem cells paved the way to the first clinical trial for the CRISPR industry. Before that, Tirtha was in charge of the synthetic mRNA platform at Moderna Therapeutics. In his academic life, he was trained as a molecular geneticist and focused on the role of small RNAs in lymphocyte development and lymphomagenesis using genetically engineered mouse models in the laboratory of Professor Klaus Rajewsky at the Immune Disease Institute of Harvard Medical School. Tirtha’s PhD thesis, completed at the Tata Institute of Fundamental Research in Mumbai, India, was on deciphering the molecular mechanism of naturally acquired immunity against the malarial parasite Plasmodium falciparum.

Tirtha Chakraborty

Chief Financial Officer

Nathan Jorgensen, PhD, MBA

Nathan Jorgensen PhD, MBA brings a comprehensive background of buy-side, sell-side, consulting, and scientific experience to his role at Vor Bio. At QIA, the sovereign wealth fund of the State of Qatar, he spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private, and specialty investments. Prior to joining QIA, Nathan led investments in therapeutics at Calamos, a growth-focused public equity investment firm with $25 billion of assets under management. Before joining Calamos, Nathan covered mid- and large-cap biotech companies at the investment bank Stifel Nicolaus.

Prior to working on Wall Street, Nathan investigated the pathobiology of Parkinson’s disease at the Columbia University Medical Center as a postdoctoral scientist. He earned an MBA from the Johnson School at Cornell University and a PhD from the University of Minnesota.

Nathan Jorgensen

Chief Commercial Officer

John King, MBA

John King, MBA is a senior commercial leader with over 20 years of experience in biotechnology and rare diseases. Prior to Vor Bio, John served as Chief Commercial Officer at Ra Pharma until August 2020, following its acquisition by UCB. During his time with Ra Pharma, John led the organization in preparing for a global commercial launch. Prior to Ra Pharma, he was Vice President, U.S. Neurology Business Unit, at Alexion Pharmaceuticals where he was responsible for building and leading the team that launched Soliris® (eculizumab) for gMG. At Alexion, he also served roles of increasing responsibility, including Vice President, Head of Global LAL-D Franchise and Vice President, Head of Global Hematology Franchise. Before joining Alexion in 2009, John served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals, including Product Director of Enbrel® (etanercept). He began his career at Ernst & Young LLP. John obtained his B.S. in business logistics and MBA from the Pennsylvania State University.

Vorbiopharma John King 5x7

Chief People Officer

Tania Philipp

Tania Philipp, Chief People Officer, brings more than 15 years of experience helping early-stage life sciences companies grow and progress. As a member of the senior leadership team, she is responsible for building a skilled and experienced team that will help Vor Bio achieve its objectives. Tania has a passion for creating a collaborative company culture and for fostering team dynamics that support individual and organizational growth. Prior to joining Vor Bio, she was Vice President and Head of Human Resources at Tango Therapeutics, where she was responsible for developing and implementing the strategic human resources vision that supported the company’s objectives and defined its culture. Before Tango, Tania held various senior human resources positions for a number of companies, including Bavarian Nordic, Mendel Biotechnology, Sunesis Pharmaceuticals, Pearl Therapeutics (acquired by AstraZeneca), and Protein Design Labs. Tania holds a master’s degree in behavioral psychology from The University of the Pacific.

Tania Philip

Senior Vice President, Head of Quality

David Phillips, MBA

David Phillips has more than 27 years of extensive expertise in establishing the foundations of quality departments in multiple pharmaceutical and biotech companies. Prior to joining Vor Bio, David served as Vice President, Head of Quality at Beam Therapeutics where he built the quality management system from the ground up, spanning all GxP areas. He also served as Vice President, Head of Quality at Kiniksa Pharmaceuticals where he established the company’s overall strategic long-term vision for quality. Before Kiniksa, David was Vice President, Quality at Shire Pharmaceuticals prior to its acquisition by Takeda. Notably, David was a core member of the team responsible for the integration of a number of programs and companies acquired by Shire and was responsible for various aspects of quality product lifecycle planning, quality aspects of geographic expansion, and technical oversight of key quality functions across a network of more than 25 locations.

David’s experience working outside of the United States – at Lonza Biologics in Singapore and at VaxGen, Inc./Celltrion in South Korea– provides him with a valuable global perspective. While at Lonza, he helped establish the country’s first biologics manufacturing park. David holds an MBA in new product development and project management and a Bachelor of Science in biochemistry and polymer chemistry from the North Carolina State University.

David Phillips, MBA

Senior Vice President, Portfolio Strategy and Program Management

Samir Vattompadam, MS

Samir Vattompadam brings deep cross-functional experience that spans commercial and clinical development, global-US-affiliate based roles, and small, medium, and large organizations across the pharmaceutical and biotech industry. Before joining Vor Bio, Samir served as Vice President, Program Executive for EQRx where he led cross-functional program strategy teams for lead candidates in immuno-oncology from late-stage studies through to regulatory submissions, including the company’s first marketing authorization applications to the MHRA and EMA for Sugemalimab in metastatic non-small cell lung cancer. Prior to EQRx, he was Executive Director, Product Team Leader at Seagen for several late-stage ADCs including TIVDAK, PADCEV, and ADCETRIS. Samir led cross-functional teams focusing on the development, submission, and approval for TIVDAK in metastatic cervical cancer. Earlier in his career, Samir served at Roche in various roles including the Global Commercial Director for GU cancers for TECENTRIQ (atezolizumab), Global Product Manager for GAZYVA (obinutuzumab) in lymphomas, and roles spanning oncology marketing, sales, and medical affairs at Roche Canada. Samir holds a Masters in Medical Sciences and a Bachelor of Science in Biology from McMaster University.

Samir Vattompadam

From the Vor Bio team

“The leadership team at Vor leads by example. They bring their authentic selves in the office, they attend company events, and they interact with everyone at every level of the company. They truly care about the people here and making the best experience for everyone.”

Janet Gee
Associate Director
Financial Planning and Analysis

“We have access to all of our executives, which is a huge advantage. They truly take an interest in helping employees grow, learn and develop. This genuine mentorship is something that makes Vor stand out.”

Lee Schwartz
Director
Human Resources

Join The Vor Bio team

Collaborate
to change
the world

Join a passionate team advancing the science and shaping the future of cancer treatments.

Board of Directors

Our Board members offer expert global biopharma experience and perspective.